Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
47 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Matrix Protein 1 (M1 or M) - Pipeline Review, H2 2016', provides in depth analysis on Matrix Protein 1 (M1 or M) targeted pipeline therapeutics. The report provides comprehensive information on the Matrix Protein 1 (M1 or M), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Matrix Protein 1 (M1 or M) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Matrix Protein 1 (M1 or M) - The report reviews Matrix Protein 1 (M1 or M) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Matrix Protein 1 (M1 or M) targeted therapeutics and enlists all their major and minor projects - The report assesses Matrix Protein 1 (M1 or M) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Matrix Protein 1 (M1 or M) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Matrix Protein 1 (M1 or M) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Matrix Protein 1 (M1 or M) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Matrix Protein 1 (M1 or M) Overview 6 Therapeutics Development 7 Matrix Protein 1 (M1 or M) - Products under Development by Stage of Development 7 Matrix Protein 1 (M1 or M) - Products under Development by Therapy Area 8 Matrix Protein 1 (M1 or M) - Products under Development by Indication 9 Matrix Protein 1 (M1 or M) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Unknown Stage Products 12 Matrix Protein 1 (M1 or M) - Products under Development by Companies 13 Matrix Protein 1 (M1 or M) - Products under Development by Universities/Institutes 15 Matrix Protein 1 (M1 or M) - Therapeutics Assessment 17 Assessment by Monotherapy/Combination Products 17 Assessment by Mechanism of Action 18 Assessment by Route of Administration 19 Assessment by Molecule Type 21 Matrix Protein 1 (M1 or M) - Companies Involved in Therapeutics Development 23 Novavax, Inc. 23 Redbiotec AG 24 Sarepta Therapeutics, Inc. 25 Matrix Protein 1 (M1 or M) - Drug Profiles 26 (influenza (virus like particle) + respiratory syncytial virus) vaccine - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 influenza (virus like particle) vaccine - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 influenza (virus like particle, tetravalent) vaccine - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 influenza [serotype A] vaccine - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 influenza [strain A/H7N9] (virus like particle, monovalent) vaccine - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 radavirsen - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 SARS (virus like particle) vaccine - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Matrix Protein 1 (M1 or M) - Featured News & Press Releases 36 Jul 30, 2015: Novavax Announces Positive Data From Phase 2 Trial of Quadrivalent Seasonal Influenza VLP 36 Nov 17, 2014: Novavax Initiates Phase 2 Clinical Trial of Quadrivalent Seasonal Influenza VLP 36 Oct 29, 2014: U.S. FDA Grants Fast Track Designation to Novavax' H7N9 Influenza Virus-Like Particle Vaccine Candidate Adjuvanted With Matrix-M 37 Sep 30, 2014: Sarepta Therapeutics Announces Favorable Safety Results from Phase I Clinical Study of Influenza Drug Candidate 38 Sep 23, 2014: Novavax H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M Delivers Positive Phase 1/2 Clinical Data 38 Mar 10, 2014: Novavax Reports Initiation of Phase 1/2 Clinical Trial of Its H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M 39 Jul 29, 2013: Novavax Initiates First Phase 1 Clinical Trial of its A Influenza Vaccine Candidate 39 Jul 08, 2013: GenScript's Rush Gene Services Help Novavax Expedite 28-day Development of H7N9 Vaccine 40 Jul 08, 2013: Novavax Initiates First Phase 1 Clinical Trial of Its A(H7N9) Influenza Vaccine Candidate 40 May 10, 2013: Novavax's H7N9 VLP Influenza Vaccine Enters Animal Testing 41 Feb 27, 2013: Novavax Announces Extension of Contract for Advanced Development of Recombinant Influenza Products and Pandemic Preparedness With HHS-BARDA 41 Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100 42 Sep 10, 2012: Novavax Delays Testing On New Experimental Flu Vaccine 43 Jul 24, 2012: NOVAVAX Provides Update on Influenza Programs 44 Mar 30, 2012: AVI BioPharma To Present Preclinical Data From Influenza Study At 22nd European Congress Of Clinical Microbiology And Infectious Diseases 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 46 Disclaimer 47
List of Tables
Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 11 Comparative Analysis by Unknown Stage Development, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Products under Development by Companies, H2 2016 14 Number of Products under Investigation by Universities/Institutes, H2 2016 15 Products under Investigation by Universities/Institutes, H2 2016 16 Assessment by Monotherapy/Combination Products, H2 2016 17 Number of Products by Stage and Mechanism of Action, H2 2016 18 Number of Products by Stage and Route of Administration, H2 2016 20 Number of Products by Stage and Molecule Type, H2 2016 22 Pipeline by Novavax, Inc., H2 2016 23 Pipeline by Redbiotec AG, H2 2016 24 Pipeline by Sarepta Therapeutics, Inc., H2 2016 25
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
